How to Get Dayvigo (Lemborexant) in New York

What Is Dayvigo and Why Does It Matter for Insomnia?

Dayvigo (lemborexant) is a dual orexin receptor antagonist, or DORA, that blocks the wake-promoting neuropeptides orexin-A and orexin-B. Unlike older sedative-hypnotics such as zolpidem, it does not act on GABA receptors, which gives it a differentiated safety profile. The FDA approved lemborexant in December 2019 for the treatment of adult insomnia characterized by difficulty with sleep onset or sleep maintenance, or both.

In the key SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared with placebo at one month. The 10 mg dose cut sleep-onset latency by a mean of 10.5 minutes more than placebo (P<0.001) on polysomnography, and both doses improved wake after sleep onset through the second half of the night [1]. These endpoints matter in practice because many patients with chronic insomnia report both trouble falling asleep and staying asleep.

Lemborexant's Schedule IV classification under the Controlled Substances Act means it carries lower abuse potential than Schedule II or III agents. That classification also makes it eligible for telehealth prescribing in New York under current state regulations, a significant access advantage for patients in rural upstate counties or those with mobility limitations in the five boroughs.

Who Can Prescribe Dayvigo in New York?

Any clinician with an active New York DEA registration and prescriptive authority for Schedule IV substances can write a lemborexant prescription. That includes physicians (MD/DO), nurse practitioners, and physician assistants.

New York granted NPs full practice authority effective January 2023 after completing 3,600 hours of supervised practice, removing the prior collaborative agreement requirement. An NP who has met that threshold can independently prescribe Dayvigo without physician co-signature. PAs in New York prescribe under a collaborative relationship with a supervising physician, and Schedule IV medications fall within their standard scope.

For patients seeking a new prescriber, sleep medicine specialists are not required. Primary care physicians, psychiatrists, and geriatricians routinely prescribe DORAs. A board-certified sleep specialist may be appropriate if the patient has suspected comorbid obstructive sleep apnea or narcolepsy, since orexin pathway drugs carry theoretical implications for those conditions. The American Academy of Sleep Medicine clinical practice guideline (2023) lists DORAs, including lemborexant, as a recommended pharmacotherapy option for chronic insomnia disorder in adults [2].

Telehealth Prescribing of Dayvigo in New York

New York permits telehealth prescribing of Schedule IV controlled substances, and several platform models now serve insomnia patients statewide. A synchronous audio-video visit satisfies the prescriber-patient relationship requirement under New York Education Law §6530 and the state's telehealth parity regulations [3].

The typical telehealth workflow looks like this. A patient completes a sleep intake questionnaire, uploads any prior sleep study results or pharmacy records, and schedules a live video consultation. During that visit, the prescriber reviews the Insomnia Severity Index score, screens for contraindicated conditions (narcolepsy, severe hepatic impairment), confirms no concurrent use of strong CYP3A inhibitors, and then transmits an electronic prescription to the patient's chosen pharmacy.

Turnaround from initial scheduling to prescription transmission usually runs 24 to 72 hours, though PA processing by the insurer may add 3 to 7 business days on top of that window. Patients in New York City, Long Island, the Hudson Valley, and upstate metros including Buffalo, Rochester, Syracuse, and Albany all have access to telehealth-based insomnia prescribing.

One practical note: some telehealth platforms restrict Schedule IV prescribing to patients who have already tried and failed at least one non-pharmacologic intervention such as cognitive behavioral therapy for insomnia (CBT-I). This is not a New York state law requirement, but rather an internal clinical protocol that aligns with AASM guideline recommendations positioning CBT-I as first-line therapy [2].

Insurance Coverage and Prior Authorization in New York

New York Medicaid covers Dayvigo with prior authorization. Most commercial plans in the state, including those offered through the NY State of Health marketplace, also cover the drug but place it on a non-preferred brand tier (typically Tier 3 or specialty tier), which triggers a PA requirement.

Prior authorization documentation typically requires the prescriber to submit:

• A confirmed diagnosis of insomnia disorder (ICD-10 codes G47.00 or G47.09)
• Documentation that the patient has tried and failed, or has a contraindication to, at least one formulary-preferred sleep agent (commonly zolpidem or suvorexant)
• A statement that non-pharmacologic therapy (CBT-I or sleep hygiene education) was offered
• Attestation that the patient does not have narcolepsy or severe hepatic impairment

The New York State Department of Financial Services requires insurers to respond to standard PA requests within 72 hours and urgent requests within 24 hours [4]. If a PA is denied, patients and prescribers can file an expedited appeal.

Without insurance, Dayvigo's average retail price exceeds $400 for a 30-day supply. Eisai offers a manufacturer savings card that can reduce out-of-pocket costs for commercially insured patients. Patients on Medicare Part D are not eligible for manufacturer coupons under federal anti-kickback rules, but may qualify for Eisai's patient assistance program if their income falls below 400% of the federal poverty level.

Pharmacy Access Across New York State

Dayvigo is stocked at major retail chains including CVS, Walgreens, Rite Aid, and independent pharmacies across New York. Mail-order pharmacies such as Express Scripts, OptumRx, and CVS Caremark also fill lemborexant prescriptions, often with 90-day supply options that reduce per-unit cost on commercial plans.

New York's 503A compounding pharmacies operate under strict oversight from the New York State Board of Pharmacy. A 503A pharmacy can compound a patient-specific prescription for lemborexant if a prescriber writes an individualized order, for example, a dose strength not commercially available or an alternative dosage form for a patient who cannot swallow tablets [4]. The compounded product must be dispensed pursuant to a valid prescription and cannot be produced in bulk for general distribution.

For patients outside the New York City metro area, mail-order remains the most reliable fulfillment channel. Rural counties in the Adirondacks, Southern Tier, and North Country may have limited retail pharmacy stock for specialty-tier branded medications. A prescriber can electronically route the prescription to a mail-order pharmacy at the time of the telehealth visit, and typical delivery runs 5 to 7 business days after PA approval.

What Labs or Evaluations Are Needed Before Starting Dayvigo?

Lemborexant does not require routine laboratory monitoring before initiation. No blood draws, liver panels, or sleep studies are mandated by the FDA-approved prescribing information. This is a meaningful distinction from some other insomnia medications or co-prescribed drugs that carry hepatotoxicity warnings.

A prescriber should, at minimum, complete a focused clinical evaluation:

• Sleep history: onset, duration, frequency of insomnia symptoms, prior treatments tried
• Screening for obstructive sleep apnea: STOP-BANG questionnaire or equivalent, since untreated OSA can worsen with sedating medications
• Hepatic function assessment: severe hepatic impairment (Child-Pugh C) is a contraindication; moderate impairment requires dose adjustment to 5 mg maximum
• Medication reconciliation: concurrent use of strong CYP3A inhibitors (itraconazole, clarithromycin) is contraindicated, and moderate CYP3A inhibitors require the dose to be limited to 5 mg
• Substance use screening: though lemborexant has lower abuse potential than benzodiazepines, a brief screen is standard clinical practice for any Schedule IV agent

If the prescriber suspects comorbid sleep apnea, a home sleep test or in-lab polysomnography may be ordered before or concurrently with starting Dayvigo. New York has more than 150 accredited sleep centers, and home sleep testing devices can be shipped directly to the patient. The AASM recommends that clinicians evaluate for and treat comorbid sleep disorders before attributing symptoms solely to chronic insomnia [2].

Dosing and What to Expect After Starting Treatment

The recommended starting dose is 5 mg taken orally once per night, within 30 minutes of intended bedtime, with at least 7 hours of sleep opportunity remaining. The dose can be increased to 10 mg if 5 mg is tolerated but insufficiently effective. No dose above 10 mg should be used.

In SUNRISE-1, the most common adverse events at the 10 mg dose were somnolence (10% vs. 1% placebo) and headache (6% vs. 4% placebo) [1]. Next-morning residual sleepiness was evaluated by the Karolinska Sleepiness Scale, and no statistically significant next-morning impairment was detected at either dose at the one-month endpoint compared with placebo [1].

Patients should avoid alcohol and other CNS depressants while taking lemborexant. The drug reaches peak plasma concentration in approximately 1 to 3 hours, and its elimination half-life is roughly 17 hours at the 10 mg dose. That long half-life contributes to sleep-maintenance efficacy but also means patients should be counseled about the possibility of morning grogginess, especially during the first week of treatment.

According to SUNRISE-2 (N=949), a 12-month extension study, lemborexant maintained efficacy on self-reported sleep onset and wake after sleep onset through 12 months without evidence of tolerance or rebound insomnia upon discontinuation [5]. This long-term data is relevant for New York patients and their prescribers when considering Dayvigo as a sustained treatment rather than a short-course rescue medication.

Transferring a Dayvigo Prescription to a New York Pharmacy

Patients relocating to New York from another state can transfer an existing lemborexant prescription, but the process involves a few steps because Dayvigo is a Schedule IV controlled substance. Under DEA regulations (21 CFR §1306.26), a Schedule III-V prescription may be transferred between pharmacies one time, unless both pharmacies share a real-time online database, in which case transfers are unlimited.

The practical path for most patients: contact the receiving New York pharmacy, provide the originating pharmacy's name, phone number, and prescription number, and the pharmacist will initiate the transfer. If the original prescription has no remaining refills, the patient will need a new prescription from a New York-licensed prescriber. A telehealth visit can accomplish this within a day or two.

Patients moving from states with stricter controlled substance transfer rules (some states limit even Schedule IV transfers) should confirm with their originating pharmacy before assuming the transfer will proceed. The receiving New York pharmacy bears responsibility for verifying the prescription's validity in the New York Prescription Monitoring Program (I-STOP) registry [4].

How Lemborexant Compares to Other Insomnia Medications Available in New York

New York prescribers have access to the full formulary of FDA-approved insomnia agents. The most commonly considered alternatives include:

Suvorexant (Belsomra): Also a DORA, approved in 2014. In a head-to-head analysis of DORA trial data, lemborexant 10 mg showed numerically greater reductions in sleep-onset latency than suvorexant 20 mg, though no direct randomized comparison has been published [5]. Suvorexant is available as a generic in some markets, potentially lowering cost.

Zolpidem (Ambien): A GABA-A receptor positive allosteric modulator. Generic zolpidem is inexpensive and widely available, which is why most PA pathways require a trial of zolpidem before approving a DORA. Zolpidem carries higher rates of complex sleep behaviors (sleepwalking, sleep-driving) per its FDA boxed warning.

Trazodone: Prescribed off-label for insomnia at 25 to 100 mg. No FDA approval for insomnia, limited controlled trial evidence at these doses, but extremely low cost and no controlled substance restrictions. Commonly tried before DORAs in step-therapy protocols.

The decision among these agents should weigh the patient's symptom profile (sleep onset vs. maintenance vs. both), prior treatment failures, comorbidities, and cost constraints. A prescriber familiar with the patient's full history is the appropriate person to make that determination.